---
title: "ALLO: ALLO-329 showed early SSc activity across LD approaches, including no lymphodepletion"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/304856871.md"
description: "In 18 Phase 1 patients, ALLO-329 showed no Grade ≥3 CRS or other key immune toxicities. In skin-predominant SSc, 8/10 achieved sustained mRSS improvement and 9/10 remained off background immunosuppression.Original document: Allogene Therapeutics, Inc. [ALLO] Press release — Nov. 9 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-11-09T13:05:44.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/304856871.md)
  - [en](https://longbridge.com/en/news/304856871.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/304856871.md)
generator: "portal-rs"
---

# ALLO: ALLO-329 showed early SSc activity across LD approaches, including no lymphodepletion

In 18 Phase 1 patients, ALLO-329 showed no Grade ≥3 CRS or other key immune toxicities. In skin-predominant SSc, 8/10 achieved sustained mRSS improvement and 9/10 remained off background immunosuppression.

Original document: Allogene Therapeutics, Inc. \[ALLO\] Press release — Nov. 9 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [ALLO.US](https://longbridge.com/en/quote/ALLO.US.md)

## Related News & Research

- [Allogene's ALLO-329 improves skin scores in 8 of 10 scleroderma patients in Phase 1 trial](https://longbridge.com/en/news/304856012.md)
- [Allogene Therapeutics (ALLO) Expected to Release Earnings on Thursday](https://longbridge.com/en/news/303544335.md)
- [Anthropic’s Valuation Target Has Slipped From $2 Trillion to Under $1.5 Trillion. Here’s Why](https://longbridge.com/en/news/305493732.md)
- [MaxLinear Stock In Focus After New AI Optics Power Chip Launch](https://longbridge.com/en/news/305513238.md)
- [Zai Lab reports sustained biomarker inhibition with ZL-1503 in Phase 1 trial](https://longbridge.com/en/news/305458594.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**